THE SAFETY AND TOLERABILITY OF NEBIVOLOL IN HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE AND LEFT VENTRICULAR EJECTION FRACTION ≥ 40%: A POPULATION-BASED COHORT STUDY (NEBIVOLOL-TR STUDY)
- Resource Type
- Authors
- TANIK, VEYSEL OZAN; ZOGHİ, MEHDİ; TEKİNDAL, MUSTAFA AGAH; YILMAZ, MEHMET MUSTAFA; BEDİR, ÖMER; ÖZTÜRK, ÖNDER; ÖZBAY, BENAY; YENİ, MEHTAP; TAŞCANOV, MUSTAFA BEĞENÇ; TANRIVERDİ, ZÜLKİF; YÜCE, ELİF İLKAY; ÇETİNARSLAN, ÖZGE; CANDEMİR, ALPER; ÖZ, AHMET; GÜL, SEFA; ULUS, TANER; SİNAN, ÜMİT YAŞAR; ER, FAHRİ; ÇALIŞKAN, SERHAT; YENERÇAĞ, MUSTAFA; KOCABAŞ, UMUT; ÇONER, ALİ; BÖYÜK, FERİT; ÇEKİCİ, YUSUF; ÇAKMAK KARAASLAN, ÖZGE; CERŞİT, SİNAN; HARBALIOĞLU, HAZAR; GÜZEL, TUNCAY; AYDIN, GÖKHAN; DOĞAN, YASEMİN; BEKAR, LÜTFÜ; EREN, HAYATİ; KIŞ, MEHMET; OKYAY, KAAN; ALTIN, CİHAN
- Source
- Subject
- safety
Male
hypertension
heart failure
Stroke Volume
complication
Coronary Artery Disease
cohort analysis
preserved ejection fraction
Ventricular Function, Left
Nebivolol
Cohort Studies
heart stroke volume
middle aged
heart left ventricle function
Humans
human
tolerability
Aged
- Language
- English
Background: This study aimed to assess the safety and tolerability of nebivolol in hypertensive patients with coronary artery disease and left ventricular ejection fraction ?40% in a Turkish cohort. Methods: A total of 1015 hypertensive patients and coronary artery disease with left ventricular ejection fraction ?40% were analyzed from 29 different centers in Turkey. Primary outcomes were the mean change in blood pressure and heart rate. Secondary outcomes were to assess the rate of reaching targeted blood pressure (
Baskent Üniversitesi
Funding: This study was supported by Baskent University Research Fund.